We are live on
!
Find out more
JSAM
J. Safra Asset Management Portfolio holdings
AUM
$2.17B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+12.24%
1 Year Est. Return
+29.66%
3 Year Est. Return
+84.26%
5 Year Est. Return
+107.54%
10 Year Est. Return
–
AUM
$1.44B
AUM Growth
+$206M
(+17%)
Cap. Flow
+$66.8M
Cap. Flow
% of AUM
4.65%
Top 10 Holdings %
Top 10 Hldgs %
69.3%
Holding
403
New
58
Increased
145
Reduced
95
Closed
36
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Listed Funds Trust Roundhill Magnificent Seven ETF
MAGS
|
+$31.4M |
| 2 |
iShares Russell 1000 Growth ETF
IWF
|
+$6.29M |
| 3 |
Invesco QQQ Trust
QQQ
|
+$6.11M |
| 4 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$5.54M |
| 5 |
JPMorgan Ultra-Short Municipal Income ETF
JMST
|
+$4.49M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$25.2M |
| 2 |
iShares Core S&P Small-Cap ETF
IJR
|
+$1.46M |
| 3 |
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
+$1.07M |
| 4 |
Tesla
TSLA
|
+$418K |
| 5 |
NXP Semiconductors
NXPI
|
+$389K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 2.8% |
| 2 | Communication Services | 1.33% |
| 3 | Financials | 1.09% |
| 4 | Consumer Discretionary | 0.77% |
| 5 | Healthcare | 0.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Surgery Partners
SGRY
$2.09B
| $4.91K | ﹤0.01% |
221
| – | – |
|
327
Celldex Therapeutics
CLDX
$3.37B
| $4.78K | ﹤0.01% |
235
-95
| -29% | -$1.85K |
|
|
MRUS
328
DELISTED
Merus
MRUS
| $4.42K | ﹤0.01% |
84
+11
| +15% | +$517 |
|
329
American Eagle Outfitters
AEO
$3.07B
| $4.01K | ﹤0.01% |
417
-167
| -29% | -$1.79K |
|
330
First Northwest Bancorp
FNWB
$105M
| $3.61K | ﹤0.01% |
469
-188
| -29% | -$1.74K |
|
331
Centene
CNC
$32.9B
| $3.53K | ﹤0.01% |
+65
| New | +$3.81K |
|
332
Alignment Healthcare
ALHC
$2.86B
| $3.5K | ﹤0.01% |
250
-78
| -24% | -$1.26K |
|
333
Procept Biorobotics
PRCT
$1.24B
| $3.17K | ﹤0.01% |
55
-1
| -2% | -$57 |
|
334
Veracyte
VCYT
$3.72B
| $3K | ﹤0.01% |
111
+59
| +113% | +$1.71K |
|
335
Caleres
CAL
$486M
| $2.85K | ﹤0.01% |
233
-85
| -27% | -$1.27K |
|
336
Phreesia
PHR
$769M
| $2.76K | ﹤0.01% |
97
-1
| -1% | -$25 |
|
337
Xenon Pharmaceuticals
XENE
$6.21B
| $2.72K | ﹤0.01% |
87
+3
| +4% | +$98 |
|
338
BioNTech
BNTX
$23.3B
| $2.66K | ﹤0.01% |
+25
| New | +$2.52K |
|
339
Crinetics Pharmaceuticals
CRNX
$8.93B
| $2.65K | ﹤0.01% |
92
+20
| +28% | +$618 |
|
|
ACLX
340
DELISTED
Arcellx
ACLX
| $2.63K | ﹤0.01% |
40
| – | – |
|
|
MASI
341
DELISTED
Masimo
MASI
| $2.52K | ﹤0.01% |
15
| – | – |
|
342
Viridian Therapeutics
VRDN
$2.61B
| $2.52K | ﹤0.01% |
180
| – | – |
|
343
Lifestance Health
LFST
$4.55B
| $2.49K | ﹤0.01% |
482
| – | – |
|
|
ONC
344
BeOne Medicines Ltd
ONC
$40.6B
| $2.42K | ﹤0.01% |
10
+1
| +11% | +$245 |
|
345
MoonLake Immunotherapeutics
MLTX
$1.47B
| $2.41K | ﹤0.01% |
51
| – | – |
|
346
Immunocore
IMCR
$1.73B
| $2.35K | ﹤0.01% |
+75
| New | +$2.33K |
|
347
CVS Health
CVS
$122B
| $2.21K | ﹤0.01% |
32
+19
| +146% | +$1.25K |
|
|
AKRO
348
DELISTED
Akero Therapeutics
AKRO
| $2.08K | ﹤0.01% |
+39
| New | +$1.77K |
|
349
Janux Therapeutics
JANX
$1B
| $1.99K | ﹤0.01% |
86
+20
| +30% | +$527 |
|
350
Cogent Biosciences
COGT
$7.1B
| $1.91K | ﹤0.01% |
266
| – | – |
|
Similar funds
ET
MIAS
SIG
TAL
ICM
IIP
ORCP
GC
J. Safra Asset Management's Q2 2025 Portfolio in Review
As of Q2 2025, J. Safra Asset Management held 403 positions worth $1.44B, up 17% from $1.23B the previous quarter. Its ten largest holdings account for 69% of the portfolio.
J. Safra Asset Management deployed $66.8M of net new capital in Q2 2025, opening 58 new positions and adding to 145 existing holdings. Its largest new stake was JPMorgan Ultra-Short Municipal Income ETF: 88,398 shares worth $4.5M.
By sector, the portfolio is most concentrated in Technology at 2.8% of assets, up from 2.2% a quarter earlier, followed by Communication Services and Financials.
On the sell side, the largest reduction was State Street SPDR Bloomberg 1-3 Month T-Bill ETF, an estimated $1.07M trimmed.
- J. Safra Asset Management's largest Q2 2025 buy was JPMorgan Ultra-Short Municipal Income ETF: 88,398 shares worth $4.5M.
- J. Safra Asset Management added most to Listed Funds Trust Roundhill Magnificent Seven ETF in Q2 2025, an estimated $31.4M increase.
- J. Safra Asset Management's biggest Q2 2025 reduction was State Street SPDR Bloomberg 1-3 Month T-Bill ETF, cutting an estimated $1.07M.
- J. Safra Asset Management fully exited State Street SPDR S&P Biotech ETF in Q2 2025, selling an estimated $25.2M.
- J. Safra Asset Management's ten largest holdings make up 69% of its $1.44B portfolio in Q2 2025.
- J. Safra Asset Management opened 58 new positions and closed 36 in Q2 2025.
- J. Safra Asset Management's portfolio value rose 17% quarter-over-quarter to $1.44B.
Based on J. Safra Asset Management's 13F filing for Q2 2025, filed 28 Jul 2025.